These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6425491)

  • 1. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay.
    Okada H; Yamazaki I; Yashiki T; Shimamoto T; Mima H
    J Pharm Sci; 1984 Mar; 73(3):298-302. PubMed ID: 6425491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.
    Okada H; Yamazaki I; Yashiki T; Mima H
    J Pharm Sci; 1983 Jan; 72(1):75-8. PubMed ID: 6402584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats III: Effect of estrous cycle on vaginal absorption of hydrophilic model compounds.
    Okada H; Yashiki T; Mima H
    J Pharm Sci; 1983 Feb; 72(2):173-6. PubMed ID: 6403693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats.
    Okada H; Yamazaki I; Sakura Y; Yashiki T; Shimamoto T; Mima H
    J Pharmacobiodyn; 1983 Jul; 6(7):512-22. PubMed ID: 6417315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.
    Okada H; Yamazaki I; Ogawa Y; Hirai S; Yashiki T; Mima H
    J Pharm Sci; 1982 Dec; 71(12):1367-71. PubMed ID: 6818337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.
    Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H
    Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentration patterns of an LHRH agonist, gonadotrophins and sex steroids after subcutaneous, vaginal, rectal and nasal administration of the agonist to pregnant rats.
    Yamazaki I
    J Reprod Fertil; 1984 Sep; 72(1):129-36. PubMed ID: 6433008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate.
    Okada H; Inoue Y; Heya T; Ueno H; Ogawa Y; Toguchi H
    Pharm Res; 1991 Jun; 8(6):787-91. PubMed ID: 1905810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
    Cassidenti DL; Sauer MV; Paulson RJ; Ditkoff EC; Rivier J; Yen SS; Lobo RA
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
    Okada H; Heya T; Ogawa Y; Shimamoto T
    J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.
    Droesch K; Muasher SJ; Brzyski RG; Jones GS; Simonetti S; Liu HC; Rosenwaks Z
    Fertil Steril; 1989 Feb; 51(2):292-7. PubMed ID: 2492234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy terminating effect of a highly active LH-RH agonist by vaginal application in rats.
    Yamazaki I
    Endocrinol Jpn; 1982 Apr; 29(2):197-207. PubMed ID: 6813109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cocaine impairs gonadotropin secretion in oophorectomized monkeys.
    Cañez MS; Samuels MH; Luther MF; King TS; Schenken RS
    Am J Obstet Gynecol; 1992 Dec; 167(6):1785-93. PubMed ID: 1471699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine and clinical effects of leuprolide in prostatic cancer.
    Vance MA; Smith JA
    Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
    Sheehan KL; Casper RF; Yen SS
    Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.
    Serafini P; Stone B; Kerin J; Batzofin J; Quinn P; Marrs RP
    Fertil Steril; 1988 Jan; 49(1):90-5. PubMed ID: 3121401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate.
    Okada H; Heya T; Ogawa Y; Toguchi H; Shimamoto T
    Pharm Res; 1991 May; 8(5):584-7. PubMed ID: 1907735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
    Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.